Inserm Transfert Initiative

Inserm Transfert Initiative (ITI) is a French seed capital firm dedicated to investing in early-stage life sciences companies that develop breakthrough innovations from French academia with high therapeutic potential. Established in 2005, ITI is a subsidiary of Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm). ITI focuses on financing innovative biotech startups in their early stages, supporting the translation of academic research into commercial applications.

The firm's investment strategy encompasses various stages, including pre-seed, seed, series A, and series B, with investment sizes up to €3 million. ITI's geographical focus is primarily on France, aligning with its mission to foster the growth of domestic biotech enterprises. The firm operates within the biotechnology and life sciences sectors, aiming to bridge the gap between academic research and industrial development.

Since its inception, ITI has been instrumental in supporting numerous biotech entrepreneurs, contributing to the advancement of medical innovations. Its role is pivotal in transforming scientific discoveries into viable commercial products, thereby enhancing public health and economic growth in the biotechnology sector.